Isomorphic Labs

Be First To Review
SKU: isomorphic-labs
Isomorphic Labs is an AI-driven drug discovery company founded by Demis Hassabis in 2021 as a spin-off from DeepMind. The company utilizes advanced AI models, including AlphaFold, to predict protein structures and interactions, aiming to revolutionize the drug discovery process. By modeling complex biological systems, Isomorphic Labs seeks to design novel therapeutics more efficiently. The company has established partnerships with pharmaceutical giants like Eli Lilly and Novartis and secured $600 million in funding to advance its mission of accelerating therapeutic development.
AI drug discovery AlphaFold protein structure prediction therapeutic development biotechnology pharmaceutical partnerships
Accelerating the drug discovery process using AI-driven predictions.
Designing novel therapeutics by modeling complex biological systems.
Collaborating with pharmaceutical companies to develop new treatments.
Reducing the time and cost associated with traditional drug development.
Isomorphic Labs operates as a commercial venture under Alphabet Inc. but maintains significant operational independence. It was founded as a spin-off from DeepMind, with its own leadership and strategic partnerships (e.g., Novartis and Eli Lilly). The company raised $600 million in external funding in 2025, demonstrating financial autonomy while remaining within Alphabet's ecosystem. Its ability to form pharmaceutical collaborations and develop proprietary AI platforms like AlphaFold 3 further underscores its semi-autonomous status.
Closed Source
Contact